Soluble CD40 Ligand in Acute Coronary Syndromes
Top Cited Papers
Open Access
- 20 March 2003
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (12), 1104-1111
- https://doi.org/10.1056/nejmoa022600
Abstract
CD40 ligand is expressed on platelets and released from them on activation. We investigated the predictive value of soluble CD40 ligand as a marker for clinical outcome and the therapeutic effect of glycoprotein IIb/IIIa receptor inhibition in patients with acute coronary syndromes.Keywords
This publication has 36 references indexed in Scilit:
- Association Between Enhanced Soluble CD40L and Prothrombotic State in HypercholesterolemiaCirculation, 2002
- Biological function of CD40 on human endothelial cells: costimulation with CD40 ligand and interleukin‐4 selectively induces expression of vascular cell adhesion molecule‐1 and P‐selectin resulting in preferential adhesion of lymphocytesImmunology, 2000
- CD40L Activation in Circulating Platelets in Patients with Acute Coronary SyndromeJMIR AI, 1999
- Reduction of atherosclerosis in mice by inhibition of CD40 signallingNature, 1998
- The Composition of Coronary-Artery PlaquesNew England Journal of Medicine, 1997
- Cardiac-Specific Troponin I Levels to Predict the Risk of Mortality in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1996
- Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial IschemiaNew England Journal of Medicine, 1996
- A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activationEuropean Journal of Immunology, 1995
- The Prognostic Value of Serum Troponin T in Unstable AnginaNew England Journal of Medicine, 1992
- Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina.Heart, 1985